Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 7/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 5/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 6/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 6/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659892 | 0.83 | AOC1 (0.37) | AOC1AOC3BACE1CYP2D6CYP2C19 | |
| SCHEMBL23199149 | 0.81 | HDAC1 (0.40) | BACE1CYP2E1CYP2C8CYP2D6CYP2A6 | |
| SCHEMBL31474141 | 0.79 | BACE1 (0.34) | BACE1IDO1 | |
| SCHEMBL29425358 | 0.79 | LOXL2 (0.47) | AOC1AOC3LOXL2BACE1IDO1 | |
| SCHEMBL15899306 | 0.79 | BACE1 (0.34) | AOC1AOC3BACE1IDO1 | |
| SCHEMBL5146700 | 0.77 | BACE1 (0.35) | BACE1 | |
| SCHEMBL15899185 | 0.76 | GPR119 (0.43) | — | |
| SCHEMBL21505637 | 0.76 | ROCK2 (0.34) | — | |
| SCHEMBL31132807 | 0.75 | KDM4C (0.42) | BACE1 | |
| SCHEMBL25192580 | 0.75 | KDM4C (0.42) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042975-A1 | Novel indolopyrrolocarbazole derivative with antitumor activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1666485-A1 | NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE WITH ANTITUMOR ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042975-A1 | Novel indolopyrrolocarbazole derivative with antitumor activity | HK1, G6PD, HK2 | AOC1 3692/4885AOC3 2538/4885LOXL2 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.